{
    "id": 10513,
    "fullName": "KIF5B - RET",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KIF5B-RET results from the fusion of KIF5B and RET, and leads to constitutive Ret kinase activity and transforming ability in culture (PMID: 22327624). KIF5B-RET fusions have been identified in lung adenocarcinoma (PMID: 22327624).",
            "references": [
                {
                    "id": 3439,
                    "pubMedId": 22327624,
                    "title": "KIF5B-RET fusions in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22327624"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3799,
        "geneSymbol": "KIF5B",
        "terms": [
            "KIF5B",
            "HEL-S-61",
            "KINH",
            "KNS",
            "KNS1",
            "UKHC"
        ]
    },
    "variant": "KIF5B - RET",
    "createDate": "08/13/2015",
    "updateDate": "04/12/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5979,
                "geneSymbol": "RET",
                "terms": [
                    "RET",
                    "CDHF12",
                    "CDHR16",
                    "HSCR1",
                    "MEN2A",
                    "MEN2B",
                    "MTC1",
                    "PTC",
                    "RET-ELE1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 11244,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AD80 inhibited RET phosphorylation and downstream signaling, and decreased viability of transformed cells expressing KIF5B-RET in culture (PMID: 28615362).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 5915,
                "therapyName": "AD80",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9186,
                    "pubMedId": 28615362,
                    "title": "Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615362"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8715,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) inhibited growth of KIF5B-RET transformed cells in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3182,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIF5B-RET were sensitive to Alecensa (alectinib) both in culture and in mouse subcutaneous transplantation models (PMID: 25349307).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3119,
                    "pubMedId": 25349307,
                    "title": "Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25349307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13751,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BLU-667 resulted in partial response in 2 patients with non-small cell lung cancer harboring KIF5B-RET (PMID: 29657135; NCT03037385).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 5530,
                "therapyName": "BLU-667",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11266,
                    "pubMedId": 29657135,
                    "title": "Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29657135"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13495,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU-667 inhibited Ret signaling and tumor growth in a patient-derived xenograft (PDX) model of non-small cell lung cancer harboring KIF5B-RET (PMID: 29657135).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 5530,
                "therapyName": "BLU-667",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11266,
                    "pubMedId": 29657135,
                    "title": "Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29657135"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8719,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of KIF5B-RET transformed cells in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21078,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, multikinase inhibitor treatment demonstrated suboptimal clinical efficacy in RET-rearranged non-small cell lung cancer patients with measurable baseline brain metastasis, with a confirmed intracranial response in 18% (2/11) of the patients; Iclusig (ponatinib) treatment resulted in no intracranial response in 3 patients harboring KIF5B-RET with evaluable brain metastasis (PMID: 30017832).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 14285,
                    "pubMedId": 30017832,
                    "title": "Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30017832"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16821,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) treatment inhibited Ret phosphorylation, resulted in tumor regression in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring KIF5B-RET (PMID: 30038711).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 12497,
                    "pubMedId": 30038711,
                    "title": "RET fusions observed in lung and colorectal cancers are sensitive to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30038711"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8727,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) treatment resulted in tumor regression in transgenic animal models of non-small cell lung cancer driven by KIF5B-RET (PMID: 27496134).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21081,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, multikinase inhibitor treatment demonstrated suboptimal clinical efficacy in RET-rearranged non-small cell lung cancer patients with measurable baseline brain metastasis, with a confirmed intracranial response rate of 18% (2/11); Sutent (sunitinib) treatment resulted in no intracranial response in a patient harboring KIF5B-RET with evaluable but non-measurable baseline brain metastasis (PMID: 30017832).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14285,
                    "pubMedId": 30017832,
                    "title": "Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30017832"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21321,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DS-5010 (BOS172738) treatment resulted in durable tumor regression in a patient-derived xenograft (PDX) model of non-small cell lung cancer harboring a KIF5B-RET fusion (Cancer Res 2019;79(13 Suppl):Abstract nr 2199).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 9591,
                "therapyName": "DS-5010",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18455,
                    "pubMedId": null,
                    "title": "BOS172738: A novel highly potent and selective RET kinase inhibitor in Phase 1 clinical development",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2199"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16310,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, RXDX-105 (CEP-32496) treatment resulted in a overall response rate of 19% (6/31) in treatment-naive non-small cell lung cancer patients with RET fusions; however, while prolonged stable disease occurred in a subset of patients with KIF5B-RET, no responses were observed, and patients harboring non-KIF5B-RET fusions had an overall response rate of 67% (6/9) (PMID: 30487236; NCT01877811).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 1002,
                "therapyName": "RXDX-105",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 14431,
                    "pubMedId": 30487236,
                    "title": "A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30487236"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11243,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RXDX-105 (CEP-32496) inhibited tumor growth in a patient-derived xenograft (PDX) model of non-small cell lung cancer harboring KIF5B-RET (PMID: 28011461).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 1002,
                "therapyName": "RXDX-105",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 9178,
                    "pubMedId": 28011461,
                    "title": "Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28011461"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21076,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, multikinase inhibitor treatment demonstrated suboptimal clinical efficacy in RET-rearranged non-small cell lung cancer patients with measurable baseline brain metastasis, with a confirmed intracranial response rate of 18% (2/11); Caprelsa (vandetanib) treatment resulted in no intracranial response in a patient harboring KIF5B-RET (PMID: 30017832).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 14285,
                    "pubMedId": 30017832,
                    "title": "Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30017832"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6989,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Caprelsa (vandetanib) treatment resulted in an objective response rate of 20% (2/10) and a median progression-free survival of 2.9 months in non-small cell lung carcinoma patients harboring KIF5B-RET fusion (J Clin Oncol 34, 2016 (suppl; abstr 9012)).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6000,
                    "pubMedId": null,
                    "title": "A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study.",
                    "url": "http://meetinglibrary.asco.org/content/163941-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21077,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, multikinase inhibitor treatment demonstrated suboptimal clinical efficacy in RET-rearranged non-small cell lung cancer patients with measurable baseline brain metastasis, with a confirmed intracranial response rate of 18% (2/11); Cometriq (cabozantinib) treatment resulted in no intracranial response in 2 patients harboring KIF5B-RET with evaluable baseline brain metastasis (PMID: 30017832).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14285,
                    "pubMedId": 30017832,
                    "title": "Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30017832"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14459,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung carcinoma patient-derived xenograft (PDX) model harboring KIF5B-RET was sensitive to treatment with Selpercatinib (LOXO-292), demonstrating tumor growth inhibition (PMID: 29912274).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11635,
                    "pubMedId": 29912274,
                    "title": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20252,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a non-small cell lung cancer patient harboring KIF5B-RET demonstrated an initial partial response and clinical improvement following treatment with Selpercatinib (LOXO-292) (PMID: 31988000).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13755,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU-667 inhibited Ret phosphorylation and proliferation of cells expressing KIF5B-RET in culture (PMID: 29657135).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 5530,
                "therapyName": "BLU-667",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11266,
                    "pubMedId": 29657135,
                    "title": "Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29657135"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8716,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) inhibited growth of KIF5B-RET transformed cells in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16178,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, multikinase inhibitor treatment demonstrated suboptimal clinical efficacy in RET-rearranged non-small cell lung cancer patients with measurable baseline brain metastasis, with a confirmed intracranial response rate of 18% (2/11); Alecensa (alectinib) treatment resulted in no intracranial response in a patient harboring KIF5B-RET with measurable baseline brain metastasis(PMID: 30017832).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14285,
                    "pubMedId": 30017832,
                    "title": "Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30017832"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2728,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lenvima (lenvatinib) inhibited Ret phosphorylation in human thyroid cancer cells expressing KIF5B-RET and blocked anchorage independent growth of transformed cells expressing KIF5B-RET in culture (PMID: 23856031).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3395,
                    "pubMedId": 23856031,
                    "title": "Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23856031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16634,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring KIF5B-RET fusion was refractory to Cometriq (Cabometyx, cabozantinib) treatment (PMID: 27683183).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 8676,
                    "pubMedId": 27683183,
                    "title": "RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27683183"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21070,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Cometriq (cabozantinib) demonstrated activity in patients with RET-rearranged lung adenocarcinoma, and among patients harboring KIF5B-RET, 20% (3/15) demonstrated a partial response and 80% (12/15) achieved stable disease (PMID: 27825636; NCT01639508).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 7513,
                    "pubMedId": 27825636,
                    "title": "Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27825636"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21069,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Cometriq (Cabometyx, cabozantinib) treatment resulted in stable disease lasted 9 months in a patient with lung adenocarcinoma harboring KIF5B-RET fusion (PMID: 30653139).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 18336,
                    "pubMedId": 30653139,
                    "title": "RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30653139"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14466,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring KIF5B-RET resistant to various treatments, including chemotherapy, immunotherapy, and Alecensa (alectinib), was treated with Selpercatinib (LOXO-292), which resulted in a clinical response, demonstrating tumor regression and reduced brain metastases (PMID: 29912274; NCT03157128).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11635,
                    "pubMedId": 29912274,
                    "title": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16686,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Alecensa (alectinib) treatment resulted in moderate tumor regression and stable disease in a lung adenocarcinoma patient harboring KIF5B-RET, but progressive disease in another patient also harboring KIF5B-RET (PMID: 27544060).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 8430,
                    "pubMedId": 27544060,
                    "title": "Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27544060"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8720,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lenvima (lenvatinib) inhibited growth of KIF5B-RET transformed cells in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21080,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, multikinase inhibitor treatment demonstrated suboptimal clinical efficacy in RET-rearranged non-small cell lung cancer patients with measurable baseline brain metastasis, with a confirmed intracranial response rate of 18% (2/11); Caprelsa (vandetanib) and Afinitor (everolimus) combination treatment resulted in no intracranial response in a patient harboring KIF5B-RET with evaluable but non-measurable baseline brain metastasis (PMID: 30017832).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 1163,
                "therapyName": "Everolimus + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 14285,
                    "pubMedId": 30017832,
                    "title": "Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30017832"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7071,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Caprelsa (vandetanib) and Afinitor (everolimus) combination treatment resulted in partial response in 83% (5/6) and stable disease in 16% (1/6) of non-small cell lung carcinoma patients harboring RET fusions, of which 4 carried KIF5B-RET, 2 carried CCDC6-RET (J Clin Oncol 34, 2016 (suppl; abstr 9069)).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 1163,
                "therapyName": "Everolimus + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6065,
                    "pubMedId": null,
                    "title": "Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.",
                    "url": "http://meetinglibrary.asco.org/content/170878-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10636,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Caprelsa (vandetanib) and Afinitor (everolimus) combination treatment resulted in a major response in a lung adenocarcinoma patient harboring KIF5B-RET fusion that was refractory to Cometriq (cabozantinib) treatment (PMID: 27683183).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 1163,
                "therapyName": "Everolimus + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8676,
                    "pubMedId": 27683183,
                    "title": "RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27683183"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14455,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing KIF5B-RET were sensitive to treatment with Selpercatinib (LOXO-292) in culture and cell line xenograft models, demonstrating decreased cell proliferation and inhibition of tumor growth (PMID: 29912274).",
            "molecularProfile": {
                "id": 10516,
                "profileName": "KIF5B - RET"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11635,
                    "pubMedId": 29912274,
                    "title": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8721,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over-expressing RET V804L in the context of KIF5B-RET were resistant to Lenvima (lenvatinib) in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13757,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU-667 inhibited proliferation of cells expressing KIF5B-RET with RET V804L in culture, and inhibited tumor growth in xenograft models (PMID: 29657135).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 5530,
                "therapyName": "BLU-667",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11266,
                    "pubMedId": 29657135,
                    "title": "Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29657135"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8717,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RET V804L in the context of KIF5B-RET conferred resistance to Cometriq (cabozantinib) in transformed cells in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8723,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over-expressing RET V804L in the context of KIF5B-RET demonstrated reduced response to Iclusig (ponatinib) in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14414,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V804L in the context of KIF5B-RET were resistant to Ofev (nintedanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8722,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over-expressing RET V804L in the context of KIF5B-RET were resistant to Caprelsa (vandetanib) in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3184,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Alecensa (alectinib) resulted in decreased autophosphorylation of Ret and reduced phosphorylation of Akt and Erk in transformed cells expressing both KIF5B-RET and RET V804L in culture (PMID: 25349307).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3119,
                    "pubMedId": 25349307,
                    "title": "Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25349307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14456,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing KIF5B-RET and RET V804L were sensitive to treatment with Selpercatinib (LOXO-292) in culture, demonstrating decreased cell proliferation (PMID: 29912274).",
            "molecularProfile": {
                "id": 12734,
                "profileName": "KIF5B - RET RET V804L"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11635,
                    "pubMedId": 29912274,
                    "title": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14418,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V804M in the context of KIF5B-RET were resistant to Caprelsa (vandetanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14419,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V804M in the context of KIF5B-RET were resistant to Ofev (nintedanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3185,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) resulted in decreased autophosphorylation of Ret and reduced phosphorylation of Akt and Erk in transformed cells expressing both KIF5B-RET and RET V804M in culture (PMID: 25349307).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3119,
                    "pubMedId": 25349307,
                    "title": "Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25349307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14457,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing KIF5B-RET and RET V804M were sensitive to treatment with Selpercatinib (LOXO-292) in culture, demonstrating decreased cell proliferation (PMID: 29912274).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11635,
                    "pubMedId": 29912274,
                    "title": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13758,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU-667 inhibited proliferation of cells expressing KIF5B-RET with RET V804M in culture (PMID: 29657135).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 5530,
                "therapyName": "BLU-667",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11266,
                    "pubMedId": 29657135,
                    "title": "Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29657135"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14415,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V804M in the context of KIF5B-RET were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11247,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AD80 inhibited RET phosphorylation and growth of transformed cells expressing KIF5B-RET with RET V804M in culture (PMID: 28615362).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 5915,
                "therapyName": "AD80",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9186,
                    "pubMedId": 28615362,
                    "title": "Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615362"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14416,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V804M in the context of KIF5B-RET were resistant to Lenvima (lenvatinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8724,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over-expressing RET G810A in the context of KIF5B-RET demonstrated increased sensitivity to Iclusig (ponatinib) in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 26416,
                "profileName": "KIF5B - RET RET G810A"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8726,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) inhibited growth of transformed cells over-expressing RET G810A in the context of KIF5B-RET in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 26416,
                "profileName": "KIF5B - RET RET G810A"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14428,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ofev (nintedanib) inhibited growth of transformed cell expressing RET G810A in the context of KIF5B-RET in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 26416,
                "profileName": "KIF5B - RET RET G810A"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8725,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over-expressing RET V804L in the context of KIF5B-RET demonstrated increased sensitivity to Lenvima (lenvatinib) in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 26416,
                "profileName": "KIF5B - RET RET G810A"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8718,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RET G810A in the context of KIF5B-RET conferred resistance to Caprelsa (vandetanib) in transformed cells in culture (PMID: 27496134).",
            "molecularProfile": {
                "id": 26416,
                "profileName": "KIF5B - RET RET G810A"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6717,
                    "pubMedId": 27496134,
                    "title": "Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11249,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing RET I788N in the context of KIF5B-RET demonstrated resistance to growth inhibition by AD80 in culture (PMID: 28615362).",
            "molecularProfile": {
                "id": 27935,
                "profileName": "KIF5B - RET RET I788N"
            },
            "therapy": {
                "id": 5915,
                "therapyName": "AD80",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9186,
                    "pubMedId": 28615362,
                    "title": "Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615362"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11251,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited RET phosphorylation and growth of transformed cells expressing RET I788N in the context of KIF5B-RET in culture (PMID: 28615362).",
            "molecularProfile": {
                "id": 27935,
                "profileName": "KIF5B - RET RET I788N"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9186,
                    "pubMedId": 28615362,
                    "title": "Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615362"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11630,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma that harbored KIF5B-RET fusion and MDM2 amplification quickly progressed after receiving Keytruda (pembrolizumab), resulted in a 135% increase of existing lung metastasis size 9 days after treatment (PMID: 28351930).",
            "molecularProfile": {
                "id": 28173,
                "profileName": "KIF5B - RET MDM2 amp"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9671,
                    "pubMedId": 28351930,
                    "title": "Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28351930"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13761,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU-667 inhibited proliferation of cells expressing KIF5B-RET with RET V804E in culture (PMID: 29657135).",
            "molecularProfile": {
                "id": 29406,
                "profileName": "KIF5B - RET RET V804E"
            },
            "therapy": {
                "id": 5530,
                "therapyName": "BLU-667",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11266,
                    "pubMedId": 29657135,
                    "title": "Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29657135"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14394,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET L730I in the context of KIF5B-RET were resistant to Lenvima (lenvatinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30004,
                "profileName": "KIF5B - RET RET L730I"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14393,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET L730I in the context of KIF5B-RET were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30004,
                "profileName": "KIF5B - RET RET L730I"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14395,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET L730I in the context of KIF5B-RET were resistant to Caprelsa (vandetanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30004,
                "profileName": "KIF5B - RET RET L730I"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14396,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET L730I in the context of KIF5B-RET were resistant to Ofev (nintedanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30004,
                "profileName": "KIF5B - RET RET L730I"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14398,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lenvima (lenvatinib) inhibited growth of transformed cell expressing RET L730V in the context of KIF5B-RET in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30005,
                "profileName": "KIF5B - RET RET L730V"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14399,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET L730V in the context of KIF5B-RET were resistant to Caprelsa (vandetanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30005,
                "profileName": "KIF5B - RET RET L730V"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14400,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET L730V in the context of KIF5B-RET were resistant to Ofev (nintedanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30005,
                "profileName": "KIF5B - RET RET L730V"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14397,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET L730V in the context of KIF5B-RET were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30005,
                "profileName": "KIF5B - RET RET L730V"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14404,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET L730V and V804M in the context of KIF5B-RET were resistant to Ofev (nintedanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30006,
                "profileName": "KIF5B - RET RET L730V RET V804M"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14401,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET L730V and V804M in the context of KIF5B-RET were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30006,
                "profileName": "KIF5B - RET RET L730V RET V804M"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14403,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET L730V and V804M in the context of KIF5B-RET were resistant to Caprelsa (vandetanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30006,
                "profileName": "KIF5B - RET RET L730V RET V804M"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14402,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET L730V and V804M in the context of KIF5B-RET were resistant to Lenvima (lenvatinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30006,
                "profileName": "KIF5B - RET RET L730V RET V804M"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14406,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lenvima (lenvatinib) inhibited growth of transformed cell expressing RET E732K in the context of KIF5B-RET in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30007,
                "profileName": "KIF5B - RET RET E732K"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14407,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) inhibited growth of transformed cell expressing RET E732K in the context of KIF5B-RET in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30007,
                "profileName": "KIF5B - RET RET E732K"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14408,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ofev (nintedanib) inhibited growth of transformed cell expressing RET E732K in the context of KIF5B-RET in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30007,
                "profileName": "KIF5B - RET RET E732K"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14405,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET E732K in the context of KIF5B-RET were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30007,
                "profileName": "KIF5B - RET RET E732K"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14412,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V738A in the context of KIF5B-RET were resistant to Ofev (nintedanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30008,
                "profileName": "KIF5B - RET RET V738A"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14409,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V738A in the context of KIF5B-RET were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30008,
                "profileName": "KIF5B - RET RET V738A"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14410,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V738A in the context of KIF5B-RET were resistant to Lenvima (lenvatinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30008,
                "profileName": "KIF5B - RET RET V738A"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14411,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V738A in the context of KIF5B-RET were resistant to Caprelsa (vandetanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30008,
                "profileName": "KIF5B - RET RET V738A"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14423,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET Y806N in the context of KIF5B-RET were resistant to Ofev (nintedanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30009,
                "profileName": "KIF5B - RET RET Y806N"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14421,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET Y806N in the context of KIF5B-RET were resistant to Lenvima (lenvatinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30009,
                "profileName": "KIF5B - RET RET Y806N"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14422,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET Y806N in the context of KIF5B-RET were resistant to Caprelsa (vandetanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30009,
                "profileName": "KIF5B - RET RET Y806N"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14420,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET Y806N in the context of KIF5B-RET were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30009,
                "profileName": "KIF5B - RET RET Y806N"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14427,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ofev (nintedanib) inhibited growth of transformed cell expressing RET A807V in the context of KIF5B-RET in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30010,
                "profileName": "KIF5B - RET RET A807V"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14424,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET A807V in the context of KIF5B-RET were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30010,
                "profileName": "KIF5B - RET RET A807V"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14425,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET A807V in the context of KIF5B-RET were resistant to Lenvima (lenvatinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30010,
                "profileName": "KIF5B - RET RET A807V"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14426,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET A807V in the context of KIF5B-RET were resistant to Caprelsa (vandetanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30010,
                "profileName": "KIF5B - RET RET A807V"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20205,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, acquired RET G810S was detected in multiple lesions from a patient with non-small cell lung cancer harboring KIF5B-RET who progressed after initial response to Selpercatinib (LOXO-292) treatment (PMID: 31988000).",
            "molecularProfile": {
                "id": 30011,
                "profileName": "KIF5B - RET RET G810S"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14433,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET G810S in the context of KIF5B-RET were resistant to Ofev (nintedanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30011,
                "profileName": "KIF5B - RET RET G810S"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14429,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET G810S in the context of KIF5B-RET were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30011,
                "profileName": "KIF5B - RET RET G810S"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14430,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET G810S in the context of KIF5B-RET were resistant to Lenvima (lenvatinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30011,
                "profileName": "KIF5B - RET RET G810S"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14432,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET G810S in the context of KIF5B-RET were resistant to Caprelsa (vandetanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30011,
                "profileName": "KIF5B - RET RET G810S"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14435,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V871I in the context of KIF5B-RET were resistant to Lenvima (lenvatinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30012,
                "profileName": "KIF5B - RET RET V871I"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14437,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ofev (nintedanib) inhibited growth of transformed cell expressing RET L730I in the context of KIF5B-RET in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30012,
                "profileName": "KIF5B - RET RET V871I"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14434,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V871I in the context of KIF5B-RET were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30012,
                "profileName": "KIF5B - RET RET V871I"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14436,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V871I in the context of KIF5B-RET were resistant to Caprelsa (vandetanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30012,
                "profileName": "KIF5B - RET RET V871I"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14439,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET F998V in the context of KIF5B-RET were resistant to Lenvima (lenvatinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30013,
                "profileName": "KIF5B - RET RET F998V"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14438,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET F998V in the context of KIF5B-RET were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30013,
                "profileName": "KIF5B - RET RET F998V"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14441,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ofev (nintedanib) inhibited growth of transformed cell expressing RET F998V in the context of KIF5B-RET in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30013,
                "profileName": "KIF5B - RET RET F998V"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14440,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET F998V in the context of KIF5B-RET demonstrated reduced sensitivity to Caprelsa (vandetanib) compared to cells expressing wild-type KIF5B-RET in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30013,
                "profileName": "KIF5B - RET RET F998V"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14445,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET M918T in the context of KIF5B-RET demonstrated reduced sensitivity to Ofev (nintedanib) compared to cells expressing wild-type KIF5B-RET in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30014,
                "profileName": "KIF5B - RET RET M918T"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14443,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET M918T in the context of KIF5B-RET were resistant to Lenvima (lenvatinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30014,
                "profileName": "KIF5B - RET RET M918T"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14444,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET M918T in the context of KIF5B-RET were resistant to Caprelsa (vandetanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30014,
                "profileName": "KIF5B - RET RET M918T"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14442,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET M918T in the context of KIF5B-RET were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30014,
                "profileName": "KIF5B - RET RET M918T"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20206,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, acquired RET G810R was detected in multiple lesions from a patient with non-small cell lung cancer harboring KIF5B-RET who progressed after initial response to Selpercatinib (LOXO-292) treatment (PMID: 31988000).",
            "molecularProfile": {
                "id": 34924,
                "profileName": "KIF5B - RET RET G810R"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20204,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, acquired RET G810C and RET G810S mutations were detected in multiple lesions from a patient with non-small cell lung cancer harboring KIF5B-RET who progressed after initial response to Selpercatinib (LOXO-292) treatment (PMID: 31988000).",
            "molecularProfile": {
                "id": 34925,
                "profileName": "KIF5B - RET RET G810C RET G810S"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20212,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, acquired RET G810C and RET G810R mutations were detected in multiple lesions from a patient with non-small cell lung cancer harboring KIF5B-RET who progressed after initial response to Selpercatinib (LOXO-292) treatment (PMID: 31988000).",
            "molecularProfile": {
                "id": 34926,
                "profileName": "KIF5B - RET RET G810C RET G810R"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20265,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ofev (nintedanib) treatment inhibited the growth of cells co-expressing KIF5B-RET and RET L881V in culture (PMID: 31118272).",
            "molecularProfile": {
                "id": 34992,
                "profileName": "KIF5B - RET RET L881V"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15288,
                    "pubMedId": 31118272,
                    "title": "Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31118272"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20267,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing KIF5B-RET and RET L881V demonstrated resistance to treatment with Cometriq (Cabometyx, cabozantinib) in culture (PMID: 31118272).",
            "molecularProfile": {
                "id": 34992,
                "profileName": "KIF5B - RET RET L881V"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15288,
                    "pubMedId": 31118272,
                    "title": "Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31118272"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20266,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing KIF5B-RET and RET L881V demonstrated resistance to treatment with Caprelsa (vandetinib) in culture (PMID: 31118272).",
            "molecularProfile": {
                "id": 34992,
                "profileName": "KIF5B - RET RET L881V"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15288,
                    "pubMedId": 31118272,
                    "title": "Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31118272"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20268,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing KIF5B-RET and RET L881V demonstrated resistance to treatment with Lenvima (lenvatinib) in culture (PMID: 31118272).",
            "molecularProfile": {
                "id": 34992,
                "profileName": "KIF5B - RET RET L881V"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15288,
                    "pubMedId": 31118272,
                    "title": "Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31118272"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 10516,
            "profileName": "KIF5B - RET",
            "profileTreatmentApproaches": [
                {
                    "id": 6476,
                    "name": "RET Inhibitor",
                    "profileName": "KIF5B - RET"
                }
            ]
        },
        {
            "id": 12734,
            "profileName": "KIF5B - RET RET V804L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 12735,
            "profileName": "KIF5B - RET RET V804M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26416,
            "profileName": "KIF5B - RET RET G810A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27935,
            "profileName": "KIF5B - RET RET I788N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28173,
            "profileName": "KIF5B - RET MDM2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29406,
            "profileName": "KIF5B - RET RET V804E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30004,
            "profileName": "KIF5B - RET RET L730I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30005,
            "profileName": "KIF5B - RET RET L730V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30006,
            "profileName": "KIF5B - RET RET L730V RET V804M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30007,
            "profileName": "KIF5B - RET RET E732K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30008,
            "profileName": "KIF5B - RET RET V738A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30009,
            "profileName": "KIF5B - RET RET Y806N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30010,
            "profileName": "KIF5B - RET RET A807V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30011,
            "profileName": "KIF5B - RET RET G810S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30012,
            "profileName": "KIF5B - RET RET V871I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30013,
            "profileName": "KIF5B - RET RET F998V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30014,
            "profileName": "KIF5B - RET RET M918T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34924,
            "profileName": "KIF5B - RET RET G810R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34925,
            "profileName": "KIF5B - RET RET G810C RET G810S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34926,
            "profileName": "KIF5B - RET RET G810C RET G810R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34992,
            "profileName": "KIF5B - RET RET L881V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}